| |
Total (n = 274)
|
APOE ϵ4 carriers (n = 129)
|
APOE ϵ4 noncarriers (n = 145)
|
P valuea
|
|---|
|
Age
|
68 (8.9)
|
69 (8.8)
|
68 (8.9)
|
0.76
|
|
Sex, female
|
48
|
53
|
44
|
0.16
|
|
Hypertension
|
44
|
36
|
50
|
0.02
|
|
Diabetes
|
8
|
8
|
9
|
0.72
|
|
Cholesterol
|
34
|
30
|
38
|
0.18
|
|
Smoking
|
8
|
6
|
10
|
0.29
|
|
ADAS-Cog/MCI
|
14 (7.0)
|
16 (7.4)
|
13 (6.2)
|
0.00
|
|
Whole brain (ml)
|
1,088 (122)
|
1,083 (110)
|
1,092 (132)
|
0.54
|
|
Hippocampal volume (ml)
|
5.91 (0.85)
|
5.83 (0.90)
|
5.98 (0.83)
|
0.17
|
- Data presented as means (standard deviation) or percentages. ADAS-Cog, Alzheimer’s Disease Assessment Scale – cognitive subscale; APOE, apolipoprotein E; MCI, mild cognitive impairment. aP values for differences in means or percentages between patients treated with placebo and those treated with galantamine.
